RxDoctor Payments Data

Teresa Drescher, NP

Family · Middletown, INNPI 1417540881

Payments from drug & device makers

$2,233in general payments, 2019–2025

Across 126 payments — averaging $17.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$534
  • AbbVie$528
  • Lilly USA, LLC$196
  • Axsome Therapeutics, Inc.$186
  • AstraZeneca$181
  • Pfizer$167
  • plus $442 from 11 others

What the payments were for

  • Food & beverage$2,233100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,233 in reported general payments places this provider in the 80th percentile of 4,392 family providers in Indiana.

See all family providers in Indiana

Medicare billing

Part B allowed, 2024
$12,061
Medicare patients
42
Services billed
146

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide15$15,766
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$13,976
OzempicSemaglutide12$11,020
Ventolin HfaAlbuterol Sulfate12$653
Albuterol Sulfate HfaAlbuterol Sulfate18$405
Atorvastatin Calcium23$282
Buspirone Hcl18$224
Omeprazole12$221
Fluticasone Propionate34$209
Gabapentin12$183
Famotidine20$157
Alendronate Sodium13$150
Losartan Potassium24$138
Ropinirole Hcl12$110
Meloxicam31$92

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$196$15,76615 claims
GSKTrelegy Ellipta$54$13,97613 claims
Novo NordiskOzempic$534$11,02012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,392 family providers in Indiana.

Other family in Middletown

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →